Pharmacological Profile
Nadolol belongs to the class of non-selective $\beta$-adrenergic antagonists. This means its action is not restricted solely to cardiac receptors (unlike cardioselective agents), but extends to $\beta$-adrenoceptors in various tissues.
In terms of its basic pharmacological properties and receptor-binding profile, the drug is very close to the prototype non-selective $\beta$-blocker, propranolol. However, the key distinction of nadolol is its significantly longer duration of clinical effect, which dictates its specific clinical applications.
Pharmacokinetics and Administration
The prolonged action of the drug is due to its pharmacokinetic parameters. The half-life ($t_{1/2}$) of nadolol is 20 to 24 hours.
This extended elimination profile provides an important practical advantage:
- The drug is administered once daily.
- Absorption and therapeutic efficacy are independent of food intake, which significantly improves patient adherence.
Indications for Use
The clinical spectrum of nadolol covers both classic cardiovascular conditions and endocrine disorders associated with hyperactivation of the sympathoadrenal system.
Main indications include:
- Hypertension — for stable blood pressure reduction.
- Chronic stable angina — to decrease myocardial oxygen demand.
- Arrhythmias — for heart rate control and stabilization.
- Myocardial infarction — as part of combination therapy.
- Thyrotoxicosis — to manage symptoms caused by excess thyroid hormones (tachycardia, tremor).